��������

Hans Grönlund is the founder and CSO of NEOGAP Therapeutics AB, a position they have held since March 2014. In addition to their role at NEOGAP, they also serve as the CSO for TCER AB and Meditec R&D Stockholm AB, starting in 2014 and 2012 respectively. Prior to these positions, Grönlund was a PI for Therapeutic immune design at Karolinska Institutet starting in 2011. Hans also served as CEO of Teaser Biotechnologies AB starting in 2010. Grönlund's career in immunology began in 2000 as an Associate Professor at Karolinska Institute. Hans then became the Vice President of Diagnostics at Athera AB from 2004 to 2008, where they launched a CE marked product. Grönlund started their career at Phadia AB in 1988 and held various managerial and directorial roles in the Reagents department until 1999.

Hans Grönlund attended Karolinska Institutet from 2000 to 2007. The degree and field of study they pursued during this period are, however, unspecified.